Heart Capex To Revenue from 2010 to 2024

HSCSW Stock  USD 0.03  0.00  0.00%   
Heart Test Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue is likely to outpace its year average in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
6.735
Current Value
7.07
Quarterly Volatility
2.44190135
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Heart Test financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Heart Test's main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.5 K, Interest Expense of 242.9 K or Selling General Administrative of 2.5 M, as well as many indicators such as Price To Sales Ratio of 349, Dividend Yield of 0.0 or PTB Ratio of 0.42. Heart financial statements analysis is a perfect complement when working with Heart Test Valuation or Volatility modules.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Latest Heart Test's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Heart Test Laboratories over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Heart Test's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Heart Test's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Heart Capex To Revenue Regression Statistics

Arithmetic Mean1.29
Geometric Mean0.31
Coefficient Of Variation189.76
Mean Deviation1.80
Median0.18
Standard Deviation2.44
Sample Variance5.96
Range7.0422
R-Value0.68
Mean Square Error3.46
R-Squared0.46
Significance0.01
Slope0.37
Total Sum of Squares83.48

Heart Capex To Revenue History

2024 7.07
2023 6.74
2022 3.55
2021 0.13
2020 0.0278

About Heart Test Financial Statements

Heart Test investors use historical fundamental indicators, such as Heart Test's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Heart Test. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 6.74  7.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Heart Stock Analysis

When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.